Article

Alzheimer's Disease Expert Dinner Symposium

The Role of Biomarkers in Early Detection and Management of Alzheimer's Disease

With the approval of amyloid-targeting therapies (ATT) in Australia, the landscape of Alzheimer’s care is rapidly changing.  Roche Diagnostics Australia is pleased to share recordings from our recent expert symposium where local and global experts in dementia revealed how cutting-edge CSF and blood-based biomarkers can unlock earlier, more accurate diagnosis — and pave the way for faster access to new treatments.

Diagnostic landscape for Alzheimer's Disease management in Australia

 

The Evolving Landscape of Alzheimer’s Diagnosis in Australia - Explore how Alzheimer’s disease is being diagnosed today — from cerebrospinal fluid (CSF) biomarkers to emerging plasma-based tests that are transforming access and accuracy.

Chair: Prof. Peter Nestor

Neurologist, Queensland Brain Institute

Prof Peter Nestor

Role of CSF Biomarkers for Alzheimer's Disease management in the real world

 

Setting Up CSF Biomarker Testing in Clinical Practice - Gain expert insights from Concord Hospital’s experience establishing CSF biomarker testing and the Young Onset Dementia Clinic — including real-world cases in amnestic AD, MCI, and non-AD dementias.

Prof. James Burrell

Behavioural Neurologist & Clinical Neurophysiologist

Prof James Burrell

Clinical utility of CSF biomarkers in early  and differential diagnosis of Alzheimer's Disease

 

CSF Biomarkers and the Power of Early Detection - Understand how CSF biomarkers align with PET imaging, hear real clinical case examples, and discover how early diagnosis can change patient outcomes.

Prof. Pablo Martinez-Lage

Neurologist at the CITA-Alzheimer Foundation, Spain

Prof Pablo Martinez-Lage

Role of biomarkers in the upcoming amyloid-targeting therapies era in Alzheimer's Disease

 

New Therapies and Next-Generation Biomarkers - learn about the latest anti-amyloid treatments and the breakthrough biomarkers pTau181 and pTau217. 

Prof Craig Ritchie

Founder & CEO of Scottish Brain Sciences, Professor of Psychiatry of Ageing - University of Edinburgh, Scotland

Prof Craig Ritchie

 

Expert Panel Discussion, Q & A

 

Hosted by Prof. Colin Masters

Professor, Florey Institute & The University of Melbourne

Prof. Colin Masters